Welcome to our dedicated page for Vera Therapeutics SEC filings (Ticker: VERA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vera Therapeutics filings document a Nasdaq-listed biotechnology company developing atacicept for serious immunological diseases, including IgA nephropathy. Form 8-K reports provide financial results, corporate updates, clinical and regulatory disclosures for the atacicept program, and material governance events such as board appointments, executive changes, and compensatory arrangements.
Proxy materials describe annual meeting matters, director elections, auditor ratification, advisory executive compensation votes, board committee structure, and related governance practices. The company’s filings also identify its Class A common stock registered on The Nasdaq Stock Market and disclose equity awards issued under director compensation and inducement grant arrangements.
Vera Therapeutics director Michael Morrissey received a grant of stock options covering 17,084 shares of Class A Common Stock. The options have a per-share exercise price of $34.35 and expire in 2036. They vest in full on the earlier of the first anniversary of the grant date or the company’s 2027 annual stockholder meeting, with full vesting upon a change in control if he remains in service.
Vera Therapeutics director Patrick G. Enright received a stock option grant for 17,084 shares of Class A common stock. The option has an exercise price of $34.35 per share and expires on May 20, 2036. All 17,084 options were held directly after the grant.
The footnote states the option will vest in full on the earlier of the first anniversary of the grant date or the date of Vera Therapeutics' 2027 annual stockholder meeting, subject to continuous service. It will also vest in full upon a change in control if his service continues through that date.
T. Rowe Price Associates, Inc. filed an Amendment No. 3 to Schedule 13G/A reporting beneficial ownership of 4,573,684 shares of Vera Therapeutics Inc. common stock, representing 6.4% of the class. The filing shows sole voting power of 4,570,810 shares and sole dispositive power of 4,573,684 shares. The filing is signed May 15, 2026, and includes a statement denying that T. Rowe Price is the beneficial owner of the securities.
Vera Therapeutics, Inc. president and CEO Marshall Fordyce reported open-market sales of a total of 18,500 shares of Class A common stock on May 12, 2026. The shares were sold in two tranches of 4,281 shares at a weighted-average price of $37.0868 and 14,219 shares at a weighted-average price of $36.6396, with actual prices ranging from $35.96 to $37.15. These transactions were carried out under a pre-established Rule 10b5-1 trading plan adopted on January 9, 2026. The filing also reports indirect holdings through a trust and a GRAT, which together hold more than 200,000 shares after these transactions.
VERA affiliate notified a proposed sale of 18,500 shares through a Form 144 filing.
The filing states 18,500 common shares are to be sold on 05/12/2026 following an exercise of stock options for cash. The excerpt also lists prior 10b5-1 sales by Marshall Fordyce: 22,951 shares on 04/14/2026 and 16,925 shares on 02/23/2026.
Vera Therapeutics reported a larger Q1 2026 loss as it ramped up spending to advance its lead kidney drug atacicept toward potential approval. Net loss widened to $121.0 million from $51.7 million a year earlier, driven by sharply higher research, manufacturing and commercialization costs.
Research and development expenses more than doubled to $86.0 million, including a $15.0 million milestone payment after the FDA accepted the Biologics License Application for atacicept in IgA nephropathy. General and administrative costs rose to $39.1 million as Vera built commercial and medical affairs capabilities. The company ended the quarter with $596.8 million in cash, cash equivalents and marketable securities and expects this to fund operations for at least 12 months. Atacicept’s Phase 3 trial met its proteinuria endpoint, and the FDA granted priority review with a PDUFA target action date of July 7, 2026.
Vera Therapeutics reported first-quarter 2026 results and highlighted progress toward potential FDA accelerated approval of atacicept for IgA nephropathy, which is under Priority Review with a PDUFA date of July 7, 2026. The company posted a net loss of $121.0 million, or $1.69 per share, compared with a net loss of $51.7 million, or $0.81 per share, a year earlier as research and development and general and administrative spending rose sharply. Vera ended March 31, 2026 with $596.8 million in cash, cash equivalents and marketable securities and believes this, together with its debt facility, will fund operations through potential atacicept approval and U.S. commercial launch and beyond.
Vera Therapeutics, Inc. President and CEO Marshall Fordyce reported open‑market sales of Class A Common Stock on April 14, 2026. He sold 14,130 shares at an average price of $43.6649, 7,921 shares at $44.5784, and 900 shares at $45.5114, totaling 22,951 shares sold.
These transactions were executed pursuant to a pre‑arranged Rule 10b5‑1(c) trading plan adopted on January 9, 2026. Following the sales, Fordyce directly holds 235,244 shares. He also has indirect holdings of 122,949 shares through a GRAT and 99,081 shares through a trust, which together include 1,032 shares acquired under the company’s 2021 Employee Stock Purchase Plan on March 13, 2026.
VERA reported a Form 144 notice showing a sale of 16,925 shares of Common Stock by Marshall Fordyce on 02/23/2026 for $710,577.51. The filing also lists 22,951 Restricted Stock Units dated 02/20/2026 as securities to be sold.
The sale is recorded on a Form 144 for Nasdaq-listed shares; the filing lists Morgan Stanley Smith Barney LLC as a broker/dealer contact. No additional proceeds treatment or holder limits are stated in the excerpt.